Clinical Policy: Vismodegib (Erivedge)
Reference Number: ERX.SPA.78
Effective Date: 03.01.15
Last Review Date: 05.19

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Vismodegib (Erivedge®) is a Hedgehog pathway inhibitor.

FDA Approved Indication(s)
Erivedge is indicated for the treatment of adults with metastatic basal cell carcinoma (BCC), or with locally advanced BCC that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.

It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Erivedge is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Basal Cell Carcinoma (must meet all):
      1. Diagnosis of BCC;
      2. Prescribed by or in consultation with an oncologist;
      3. Age ≥ 18 years;
      4. Request meets one of the following (a or b):
         a. Dose does not exceed 150 mg per day;
         b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

   Approval duration: Length of Benefit

B. Other diagnoses/indications
   1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy
   A. Basal Cell Carcinoma (must meet all):
      1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions, or documentation supports that member is currently receiving Erivedge for BCC and has received this medication for at least 30 days;
      2. Member is responding positively to therapy;
      3. If request is for a dose increase, request meets one of the following (a or b):
         a. New dose does not exceed 150 mg per day;
         b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

   Approval duration: Length of Benefit
B. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.
      Approval duration: Duration of request or 6 months (whichever is less); or
   2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents

IV. Appendices/General Information
   Appendix A: Abbreviation/Acronym Key
   BCC: basal cell carcinoma
   FDA: Food and Drug Administration
   NCCN: National Comprehensive Cancer Network

   Appendix B: Therapeutic Alternatives
   Not applicable

   Appendix C: Contraindications/Boxed Warnings
   • Contraindication(s): none reported
   • Boxed warning(s): embryo-fetal toxicity

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCC</td>
<td>150 mg PO QD</td>
<td>150 mg/day</td>
</tr>
</tbody>
</table>

VI. Product Availability
Capsules: 150 mg

VII. References

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy created.</td>
<td>02.15</td>
<td>03.15</td>
</tr>
<tr>
<td>Added max dosing criteria per PI.</td>
<td>08.16</td>
<td>09.16</td>
</tr>
<tr>
<td>Converted to new template.</td>
<td>07.17</td>
<td>08.17</td>
</tr>
<tr>
<td>Age and pregnancy precaution added.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Approval periods increased from 3/6 to 6/12 months. References updated.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2Q 2018 annual review: Added prescriber requirement. Updated NCCN Compendium supported use in BCC with nodal or distant metastases. Added continuity of care language to section II. Increased approval durations to length of benefit. References reviewed and updated.</td>
<td>02.08.18</td>
<td>05.18</td>
</tr>
</tbody>
</table>
Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>2Q 2019 annual review: no significant changes; summarized NCCN and FDA approved uses for improved clarity by removing specific requirements for locally advanced, nodal, or distant metastasis (approach aligns with Odomzo); references reviewed and updated.</td>
<td>02.04.19</td>
<td>05.19</td>
</tr>
</tbody>
</table>

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2015 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.